Lyrica is reimbursable from this month

From June 1, Pfizer’s Lyrica (pregabalin) could be reimbursed by health insurance, as an adjunct therapy for neuropathic pain and partial seizures with or without secondary generalization in cancer patients.

Lyrica is considered to have a low potential for abuse, and a limited dependence liability if misused, and is thus classified as a Schedule V drug in the U.S.

Its therapeutic effect a...